HMGB2 and ovarian cancer: In vitro assays revealed a significant decrease in tumor cell proliferation across multiple cancer cell lines, including MDA-MB-231 (breast cancer), HeLa (cervical cancer), SKOV3 (ovarian cancer), and Ishikawa (endometrial cancer), following HMGB2 knockdown and Palbociclib treatment.